全氟己基辛烷滴眼液治疗中国患者睑板腺功能障碍相关干眼症:一项随机临床试验
这项随机、多中心、双盲、生理盐水对照的3期临床试验纳入312例中国睑板腺功能障碍相关干眼症患者,评估全氟己基辛烷滴眼液每日4次治疗57天的疗效与安全性。第57天时,全氟己基辛烷组角膜荧光素染色评分和眼干涩评分较基线的改善均优于对照组,差异有统计学意义,且耐受性和安全性良好。
要点
- 第57天全氟己基辛烷组角膜荧光素染色评分较基线下降3.8分,对照组下降2.7分,估计均数差为-1.14(95%CI,-1.70至-0.57;P < .001)。
- 第57天全氟己基辛烷组眼干涩评分较基线下降38.6分,对照组下降28.3分,估计均数差为-12.74(95%CI,-17.20至-8.28;P < .001)。
- 治疗中出现的不良事件在全氟己基辛烷组为34例(21.8%),对照组为40例(25.6%)。
核心结论
- 全氟己基辛烷滴眼液显著改善睑板腺功能障碍相关干眼症的体征和症状,起效快,57天内耐受性和安全性良好。
- 作者认为,若结果能被独立证实并在更长时间内验证,这些发现支持使用该滴眼液。
研究设计与样本
- 随机、多中心、双盲、生理盐水对照的3期临床试验,于2021年2月4日至2022年9月7日在中国15家医院眼科招募患者。
- 共纳入312例睑板腺功能障碍相关干眼症患者,按1:1随机分配接受全氟己基辛烷滴眼液或0.6%氯化钠滴眼液,每日4次。
主要发现
- 第57天角膜荧光素染色评分较基线变化:全氟己基辛烷组平均(SD)为-3.8(2.7),对照组为-2.7(2.8),估计均数差为-1.14(95%CI,-1.70至-0.57;P < .001)。
- 第57天眼干涩评分较基线变化:全氟己基辛烷组平均(SD)为-38.6(21.9),对照组为-28.3(20.8),估计均数差为-12.74(95%CI,-17.20至-8.28;P < .001)。
- 全氟己基辛烷组在疼痛(平均[SD]评分26.7[23.7] vs -18.7[22.5];P = .003)、干眼症状感知(-38.1[25.1] vs -23.7[27.6];P < .001)和干涩频率(-43.3[23.8] vs -29.1[24.8];P < .001)方面也较对照组减轻。
- 治疗中出现的不良事件在全氟己基辛烷组为34例(21.8%),对照组为40例(25.6%)。
关键数值与推荐
- 入选标准包括:患者主诉干眼症状、眼表疾病指数≥25、泪膜破裂时间≤5秒、无麻醉Schirmer I试验5分钟结果≥5 mm、总角膜荧光素染色评分4至11分、睑板腺功能障碍评分≥3分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者在结论中指出,若结果能被独立证实并在更长时间内验证,这些发现支持使用该滴眼液。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Meibomian gland dysfunction (MGD) is a leading cause of evaporative dry eye disease (DED). Medical and surgical management for DED is limited; therefore, new treatment options are sought. OBJECTIVE: To evaluate the efficacy and safety of SHR8058 (perfluorohexyloctane) eye drops in Chinese patients with DED associated with MGD through 57 days. DESIGN, SETTING, AND PARTICIPANTS: This was a randomized, multicenter, double-masked, saline-controlled, phase 3 clinical trial conducted from February 4, 2021, to September 7, 2022. Patients were recruited from the departments of ophthalmology in 15 hospitals in China. Patients with DED associated with MGD were enrolled between February 4 and July 1, 2021. The diagnosis was based on patient complaint of DED symptoms, an ocular surface disease index of 25 or higher, tear film break-up time of 5 seconds or less, Schirmer I test without anesthesia results of 5 mm or more at 5 minutes, total corneal fluorescein staining (tCFS) score of 4 to 11, and an MGD score of 3 or higher. INTERVENTIONS: Eligible participants were randomly assigned 1:1 to receive perfluorohexyloctane eye drops or 0.6% sodium chloride [NaCl]) 4 times per day. MAIN OUTCOMES AND MEASURES: The primary end points were the changes from baseline in tCFS and eye dryness scores at day 57. RESULTS: A total of 312 participants were included in the analysis: 156 (mean [SD] age, 45.4 [15.2] years; 118 female [75.6%]) in the perfluorohexyloctane group and 156 (mean [SD] age, 43.7 [15.1] years; 127 female [81.4%]) in the NaCl group. Both primary end points were achieved, ie, changes from baseline at day 57 of tCFS score (mean [SD], -3.8 [2.7] vs -2.7 [2.8]) and eye dryness score (mean [SD], -38.6 [21.9] vs -28.3 [20.8]) in the perfluorohexyloctane group were superior to the control group, with estimated mean differences of -1.14 (95% CI, -1.70 to -0.57; P < .001) and -12.74 (95% CI, -17.20 to -8.28, P < .001), respectively. Improvements on both end points appeared to be noted on day 29 and day 15, respectively, and maintained through day 57. Compared with the control, perfluorohexyloctane eye drops also alleviated symptoms including pain (mean [SD] tCFS score, 26.7 [23.7] vs -18.7 [22.5]; P = .003), awareness of DED symptoms (mean [SD] tCFS score, -38.1 [25.1] vs -23.7 [27.6]; P < .001), and frequency of dryness (mean [SD] tCFS score, -43.3 [23.8] vs -29.1 [24.8]; P < .001). Treatment-emergent adverse events occurred in 34 participants (21.8%) and 40 participants (25.6%) in the perfluorohexyloctane and control groups, respectively. CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial demonstrate that perfluorohexyloctane eye drops significantly ameliorated the signs and symptoms of DED associated with MGD with a rapid efficacy as well as satisfactory tolerability and safety through 57 days. Findings support the use of these eye drops if results can be confirmed independently and over longer time periods. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05515471.
引用
- Tian L, Gao Z, Zhu L, et al. Perfluorohexyloctane Eye Drops for Dry Eye Disease Associated With Meibomian Gland Dysfunction in Chinese Patients: A Randomized Clinical Trial. JAMA Ophthalmol. 2023. PMID: 36929413. doi:10.1001/jamaophthalmol.2023.0270
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。